Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re getting ready for another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday. Source: Shutterstock But hold on just a second. Before that, make ...
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected i...
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022 Co...
Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...
CARA's IV Korsuva for the treatment of severe itching (pruritus) in CKD patients on dialysis has a PDUFA date of August 23, 2021. It appears that the FDA does not have issues with IV Korsuva's safety and efficacy, but the remaining NDA approval risks appear to be mainly potential CMC ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The PDUFA action date for Cara’s main drug KORSUVA (treats pruritus) is August 23, 2021. If KORSUVA is approved, Cara would have sole access to a large patient market with no FDA-approved therapy. I calculate Cara to be extremely undervalued by P/S and PEG valuations and as...
Cara Therapeutics, Inc. (CARA) Q2 2021 Earnings Conference Call August 9, 2021 4:30 P.M. ET Company Participants Cole Herlitz-Ferguson - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Thomas Reilly - Chief Financial Officer Conference Call Participants Jessica...
Image source: The Motley Fool. Cara Therapeutics, inc (NASDAQ: CARA) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cara Therapeutics, inc (CARA) Q2 2021 Earnings Call Transcript
Cara (NASDAQ:CARA) says following a potential FDA approval of Korsuva injection for chronic kidney disease-associated pruritus in hemodialysis later this month, it would launch the drug this half of the year. Korsuva (difelikefalin), which has Priority Review status, has an FDA action date of...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...